News

Triple therapy with fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) can reduce mortality rates among people with chronic obstructive pulmonary disease (COPD) more than VI treatment with either FF or UMEC, a new analysis of trial data suggests. The findings were published in the American…

FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…

New official guidelines have been published by the American Thoracic Society (ATS) for the treatment of chronic obstructive pulmonary disease (COPD). Among the new recommendations, the combination of long-acting beta two agonists (LABA) and long-acting muscarinic antagonists (LAMA) is recommended over either therapy alone to treat people with COPD…

MP1032, an anti-inflammatory molecule developed by MetrioPharm, inhibits the formation of 3-nitrotyrosine — a biomarker of nitrogen reactive species — induced by cigarette smoke in the air sacs of a lung model of chronic obstructive pulmonary disease (COPD), a study has found. The research suggests that MP1032…

People with chronic obstructive pulmonary disease (COPD) need to continue to use maintenance medications as prescribed throughout the COVID-19 pandemic, and do all they can to avoid infection, the American Lung Association said in an update. This virus poses a considerably greater risk of serious complications to these patients and…

A single dose of a pressurized metered-dose inhaler formulation of ensifentrine (RPL544) significantly improved lung function, compared to a placebo, in people with moderate-to-severe chronic obstructive pulmonary disease (COPD), Verona Pharma announced. These results are from part A, the single-dose part, of a Phase 2 trial (NCT04091360) underway in two…

At 3 a.m. on July 6, 2003, Miami resident Jeffrey Goldstein got a call that would change his life. Doctors at the Duke University Lung Transplant Clinic had found a lung donor match for Goldstein, who had been diagnosed with pulmonary fibrosis two years earlier. Nearly 17 years…

People with chronic obstructive pulmonary disease (COPD) are among the most vulnerable to COVID-19 infections, being even more likely to develop severe disease or to be admitted to intensive care units (ICU) than those with diseases like high blood pressure or diabetes, an analysis of several…

Low levels of the protein CC16 in blood are associated with worse lung function and more severe disease among people with chronic obstructive pulmonary disease (COPD), a new study suggests. The study, “Reduced Serum Concentration of CC16 Is Associated with Severity of Chronic Obstructive Pulmonary Disease…